Northwestern University Feinberg School of Medicine

Department of Medicine

Clinical Trials

As part of an academic medical center, the Division of Infectious Diseases within the Department of Medicine at Northwestern University Feinberg School of Medicine (Feinberg) aims to improve the human health through scientific research.

About Clinical Trials
Clinical trials test or study drugs, surgical procedures, medical devices, or interventions with human subjects. They look to determine their safety and effectiveness in relation to treating specific diseases. Clinical trials are part of clinical research and are at the heart of all medical advances.

Division of Infectious Diseases - Department of Medicine
The following searchable list includes all the Division of Infectious Diseases - Department of Medicine clinical trials currently looking for participants.

Contact Us
Please feel free to contact us with inquiries about any of our ongoing research.

Trials
A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV
A5324 is a randomized, double-blinded, placebo-con…
A5324 is a randomized, double-blinded, placebo-controlled study for HIV-infected individuals with an undetectable HIV viral load who have at least mild neurocognitive impairment. Participants will be randomized to add either maraviroc plus dolutegravir, dolutegravir alone, or placebo to their current anti-HIV medications. The main purpose of the study is to see if intensification with maraviroc and dolutegravir will improve neurocognitive performance and functioning in persons who have at least mild neurocognitive impairment.
• HIV-1 infected persons at least 18 years of age
• On current HIV medications for at least 12 months
• No prior or current use of any integrase inhibitor or maraviroc
• HIV viral load less than 50 copies
• Screening neuropsychological tests showing problems with memory, thinking or daily tasks
Taiwo, Babafemi OTaiwo, Babafemi O
NCT02519777 STU00200413
More Info

For more information on this study please contact us:

Berzins, Baiba Ingrida 312 695 5012
HIV acquisition among African-born US residents
We are doing this study with people who have been diagnosed with HIV infection and were born in Africa. We want to learn about how and where people born in Africa who now live in the U.S. became infected with HIV, and how often and where they were scre…
We are doing this study with people who have been diagnosed with HIV infection and were born in Africa. We want to learn about how and where people born in Africa who now live in the U.S. became infected with HIV, and how often and where they were screened for HIV, so that barriers for HIV diagnosis can be identified. This study involves a one-time in-person interview (30 to 45 minutes) about the participants HIV testing history, risk factors, and sexual behaviors.
Have an HIV diagnosis in 2000 or later year; African country of birth or citizenship, but currently living in the U.S.; Male or Female at least 18 years of age; English-speaking
Taiwo, Babafemi OTaiwo, Babafemi O
STU00200911
More Info

For more information on this study please contact us:

Berzins, Baiba Ingrida 312 695 5012
HFN - CHART
The purpose of this study is to better understand how the heart’s health and function is affected by HIV infection and use of active antiretroviral therapy. We will evaluate how well your heart is working and measure proteins and chemicals in your blood. This study consists of a serie…
The purpose of this study is to better understand how the heart’s health and function is affected by HIV infection and use of active antiretroviral therapy. We will evaluate how well your heart is working and measure proteins and chemicals in your blood. This study consists of a series of tests that may be completed in one visit or may be divided between two or more visits. We expect up to 20 people here will be in this research study out of approximately 200 people in the entire study nationally.
Inclusion Criteria:
Age >40 years
HIV antibody positive
On HAART for >6 months (HIV positive cohort only)
History of adequate viral suppression as defined by HIV RNA level <200 copies/mL in the past 6 months
LVEF >50%

Exclusion Criteria:
Past EF <50%
Moderate or severe valve stenosis or regurgitation, or past repair or replacement
Percutaneous or surgical revascularization or active angina
Persistent atrial fibrillation
BP>160mmHg SBP or >100mmHg DBP
Comorbid inflammatory disease (e.g. RA or SLE)
Active cancer or cancer chemotherapy treatment in the prior year (except skin cancer that did not require chemotherapy or radiation)
Chronic use of steroids or anti-inflammatory therapy
GFR <30 mL/min
Active in a clinical trial with investigational product
Contraindication to cMR or gadolinium injection (such as severe claustrophobia, metal implants, etc.)
Shah, Sanjiv JShah, Sanjiv J
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02860156 STU00203898
More Info

For more information on this study please contact us:

Sanchez, Cynthia 312 695 5097